14亿元,荣昌生物VEGF/FGF授权给参天制药8月19日,荣昌生物发布公告,将VEGF/FGF融合蛋白RC28-E在大中华区、韩国、泰国、越南、新加坡、菲律宾、印度尼西亚及马来西亚的权益授权给参天制药。根据协议,荣昌生物获得2.5亿元预付款,5.2亿元开发及监管里程碑,5.25亿元销售里程碑,以及高个位数至双位数百分比的销售分成,协议总金额13.95亿元。RC28-E注射液是荣昌生物自主研发的...
Source Link14亿元,荣昌生物VEGF/FGF授权给参天制药8月19日,荣昌生物发布公告,将VEGF/FGF融合蛋白RC28-E在大中华区、韩国、泰国、越南、新加坡、菲律宾、印度尼西亚及马来西亚的权益授权给参天制药。根据协议,荣昌生物获得2.5亿元预付款,5.2亿元开发及监管里程碑,5.25亿元销售里程碑,以及高个位数至双位数百分比的销售分成,协议总金额13.95亿元。RC28-E注射液是荣昌生物自主研发的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.